Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03704077
Title An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Nivolumab

Paclitaxel + Ramucirumab

Nivolumab + Paclitaxel

Nivolumab + Paclitaxel + Relatlimab

Nivolumab + Relatlimab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | DEU | CAN


No variant requirements are available.